A detailed history of Rhumbline Advisers transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 156,853 shares of CTXR stock, worth $83,132. This represents 0.0% of its overall portfolio holdings.

Number of Shares
156,853
Previous 150,123 4.48%
Holding current value
$83,132
Previous $114,000 23.68%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
$0.6 - $0.9 $4,038 - $6,057
6,730 Added 4.48%
156,853 $141,000
Q4 2023

Feb 08, 2024

SELL
$0.65 - $0.86 $890 - $1,178
-1,370 Reduced 0.9%
150,123 $114,000
Q3 2023

Nov 09, 2023

BUY
$0.65 - $1.25 $4,722 - $9,082
7,266 Added 5.04%
151,493 $103,000
Q2 2023

Aug 08, 2023

BUY
$1.08 - $1.65 $155,765 - $237,974
144,227 New
144,227 $173,000
Q2 2022

Aug 11, 2022

SELL
$0.88 - $1.87 $109,819 - $233,366
-124,795 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$1.38 - $1.89 $28,726 - $39,342
20,816 Added 20.02%
124,795 $223,000
Q4 2021

Feb 10, 2022

SELL
$1.51 - $2.2 $5,964 - $8,690
-3,950 Reduced 3.66%
103,979 $160,000
Q3 2021

Nov 12, 2021

BUY
$1.74 - $2.6 $6,798 - $10,158
3,907 Added 3.76%
107,929 $219,000
Q2 2021

Aug 05, 2021

BUY
$1.51 - $4.23 $157,073 - $440,013
104,022 New
104,022 $362,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $77.4M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.